Hepion Pharmaceuticals Finalizes CEO Separation Agreement, Discloses $255K Payout Amidst Going Concern Warning

summarizeSummary

Hepion Pharmaceuticals, Inc. entered into a separation agreement with its former CEO, Dr. Kaouthar Lbiati, involving a total payout of $255,625 plus COBRA reimbursements, further impacting the company's critical cash position.

check_boxKey Events

• Former CEO Separation Terms Finalized

  The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati, including a $225,000 payment and a $30,625 pro-rata cash bonus, totaling $255,625, plus 6 months of COBRA reimbursements.

• Director Resignation Confirmed

  Dr. Lbiati also formally resigned as a director of the company on April 13, 2026, following her prior resignation as CEO.

• Significant Cash Outflow Amidst Financial Distress

  The $255,625 payout represents a substantial portion of the company's market capitalization and further strains its limited cash reserves, which are projected to run out by Q3 2026, as previously disclosed in its going concern warning.

auto_awesomeAnalysis

This filing details the financial terms of the former CEO's separation, which includes a significant payout of over $255,000. For a company with a market capitalization of approximately $550,000 and a previously disclosed "going concern" warning with cash expected to run out by Q3 2026, this cash outflow is highly material and exacerbates its financial distress. Investors should view this as a further depletion of critical resources for a company already struggling with liquidity and delisting.